Conestoga Capital Advisors LLC Purchases 6,872 Shares of Repligen Co. (NASDAQ:RGEN)

Conestoga Capital Advisors LLC grew its position in Repligen Co. (NASDAQ:RGEN) by 0.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 947,582 shares of the biotechnology company’s stock after buying an additional 6,872 shares during the period. Repligen accounts for about 1.8% of Conestoga Capital Advisors LLC’s portfolio, making the stock its 21st largest position. Conestoga Capital Advisors LLC’s holdings in Repligen were worth $136,395,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the company. Slow Capital Inc. increased its position in shares of Repligen by 3.3% during the fourth quarter. Slow Capital Inc. now owns 16,760 shares of the biotechnology company’s stock worth $2,412,000 after purchasing an additional 534 shares in the last quarter. Ballentine Partners LLC raised its stake in Repligen by 4.0% in the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 72 shares during the last quarter. UMB Bank n.a. boosted its holdings in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 110 shares in the last quarter. Diversify Wealth Management LLC increased its holdings in shares of Repligen by 74.2% during the fourth quarter. Diversify Wealth Management LLC now owns 3,342 shares of the biotechnology company’s stock valued at $518,000 after acquiring an additional 1,423 shares in the last quarter. Finally, Artemis Investment Management LLP raised its position in shares of Repligen by 18.4% in the 4th quarter. Artemis Investment Management LLP now owns 153,832 shares of the biotechnology company’s stock valued at $22,143,000 after purchasing an additional 23,905 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Down 0.8 %

RGEN opened at $166.21 on Monday. The firm’s fifty day simple moving average is $154.24 and its two-hundred day simple moving average is $147.84. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the previous year, the firm posted $0.23 EPS. Repligen’s revenue was up 9.7% compared to the same quarter last year. As a group, research analysts predict that Repligen Co. will post 1.54 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on RGEN shares. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Wolfe Research started coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. Canaccord Genuity Group initiated coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Finally, HC Wainwright lowered their target price on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $184.73.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.